Achieve Life Sciences Inc (NQ: ACHV )

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

March 05, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Life Science Investor Forum: Presentations Now Available for Online Viewing

December 15, 2023

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

March 29, 2023

Topline Data Expected in 2Q 2023

Life Science Investor Forum Agenda Announced for December 14th, 2023

December 12, 2023

Achieve Life Sciences Inc. (NASDAQ: ACHV) Climbs to New 52-Week High

April 26, 2023

Via Investor Brand Network

Achieve Life Sciences Announces Refresh to Board of Directors

March 30, 2023

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

March 08, 2023

Topline Data Expected in 2Q 2023

Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

March 03, 2023

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023

March 02, 2023

Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

February 07, 2023

Topline Data Expected in 2Q 2023

Achieve Life Sciences Announces Granting of New Hire Inducement Award

March 17, 2023

Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference

February 02, 2023

Achieve Life Sciences Announces Granting of New Hire Inducement Award

January 27, 2023

Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

January 09, 2023

Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation

December 21, 2022

Achieve Life Sciences Announces Private Placement of $18.9 Million

November 15, 2022

Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial

November 08, 2022

Phase 2 ORCA-V1 Data Expected in 1H2023

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022

October 31, 2022

36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

January 28, 2022

RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public...

From MicroCap Rodeo

36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022

May 16, 2022

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public...

From MicroCap Rodeo

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...

Achieve Life Sciences to Participate in Upcoming Investor Conferences

September 15, 2021

Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference

Topics Death

Exposures Death

September 14, 2021

SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...

Topics Death Intellectual Property

Exposures Death Intellectual Property

Achieve Life Sciences to Participate in Two Upcoming Investor Conferences

September 09, 2021

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards

Topics Death

Exposures Death

August 13, 2021

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and...

Topics Death Intellectual Property

Exposures Death Intellectual Property

Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update

August 11, 2021

Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen

Topics Death Intellectual Property

Exposures COVID-19 Death Intellectual Property

August 11, 2021

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...

Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021

Topics Death Intellectual Property

Exposures Death Intellectual Property Product Safety

August 03, 2021

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...

Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use

July 22, 2021

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization...

Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline

Topics Death Intellectual Property

Exposures Death Intellectual Property Product Safety

June 29, 2021

ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE /...